Sample Size Matters: A Guide for Surgeons by Guller, Ulrich & Oertli, Daniel
Sample Size Matters: A Guide for Surgeons
Ulrich Guller, M.D., M.H.S., Daniel Oertli, M.D., F.A.C.S.
Department of Surgery, Divisions of General Surgery and Surgical Research, University of Basel, Spitalstrasse 21, CH-4031, Basel, Switzerland
Published Online: April 21, 2005
Abstract. Considerations of sample size computations in the medical
literature have gained increasing importance over the past decade and
are now often mandatory for scientific grant proposals, protocols, and
publications. However, many surgeons are ill-prepared to understand the
parameters on which the appropriate sample size is based. The present
article has several objectives: first, to review the need for sample size
considerations; second, to explain the ingredients necessary for sample
size computations in simple, nonmathematic language; third, to provide
options for reducing the sample size if it seems impracticably large; and
fourth, to help avoid some of the more common mistakes encountered
when computing sample sizes.
How many patients do I need to enroll in my study? This is the
inevitable question that forms the preface to any clinical study.
The importance of such a consideration is clear: even the most
thoroughly planned and well executed investigation may fail to
answer the research question if the sample size is too small. On
the other hand, enrolling more patients than necessary in a study
is not cost-effective and could potentially be unethical [1]. The
objective of sample size computations is to estimate accurately the
appropriate number of patients to be enrolled in a given study.
Performing accurate sample size computations represents a
critical step in the design of scientific studies. However, some
surgeons are ill-prepared to understand the various parameters
that affect the sample size. The failure to carefully consider
sample size and power represents a worrisome, yet frequent
phenomenon [2–4]. Because simplistic and sometimes ill-in-
formed applications of mathematic formulas are part of the
problem we seek to remedy, this review provides a series of
nonmathematic explanations of the key issues of sample size
computations coupled with some intuitive examples drawn from
the field of surgery. It is hoped that this artical facilitates sur-
geons understanding of the cardinal importance of computing an
appropriate sample size and as a result improve their ability to
perform methodologically sound research.
Ingredients for Sample Size Computations
Here, we briefly discuss the different various parameters that
affect the sample size.
One-sided versus Two-sided Hypothesis
To understand sample size computations, it is necessary to
understand the meanings of the null hypothesis and the alter-
native hypothesis, as well as the difference between a one-sided
(or one-tailed) versus two-sided (or two-tailed) hypothesis. The
null hypothesis is the hypothesis that no difference exists between
the study groups. In a randomized clinical trial, for example, the
null hypothesis states that there is no difference between study
arms for the endpoint under investigation (e.g., disease-free or
overall survival, postoperative complications, postoperative
mortality). Conversely, the alternative hypothesis (the one the
investigator wants to prove) is that there exists a significant dif-
ference between study arms. The objective is to collect data and
ascertain whether the results provide evidence against the null
hypothesis.
The null and alternative hypotheses can be stated either one- or
two-sided. A two-sided alternative hypothesis states that a dif-
ference exists between two treatments, with the possibility of ei-
ther treatment being superior to the other. Conversely, a one-
sided alternative hypothesis specifies in advance (a priori) that
one treatment is believed to be superior to the other. An inves-
tigator who compares a new treatment to the standard treatment
may have reason to believe that the new therapy is better based on
pilot studies or data from the current literature. Choosing a one-
sided alternative hypothesis increases the power for a given
sample size [5]. Although two-sided alternative hypotheses are
commonly used throughout the medical literature, some investi-
gators argue that a one-sided hypothesis is more appropriate in
certain situations. Here are some general guidelines regarding
this issue [6].
1. Unless you can state with absolute certainty that a difference
between two interventions can only go in one direction, a two-
sided alternative hypothesis should be used [7]. For instance,
although you might firmly believe that a new chemotherapy
regimen for stage III colon cancer patients improves overall
survival, patients might actually die earlier owing to unex-
pectedly severe side effects. Moreover, there are funding
agencies that require two-sided alternative hypotheses,
regardless of how strong the previous evidence is that the ef-
fect goes in only one direction.
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2. If you use a one-sided alternative hypothesis, it must be stated
in advance (a priori hypothesis), specifying the intervention
that is believed to be superior [7, 8].
3. There have been instances in medical science when, at the end
of a trial yielding a marginally significant two-tailed p- value
(based on a two-sided alternative hypothesis, e.g., p = 0.06)
for the difference between interventions, the p-value was
switched to a one-tailed p-value (0.03) to obtain a statistically
significant result. Such behavior is misleading and should be
abandoned.
Type I Error and Type II Error
There are two ways study findings can err. [6, 9–11].
1. The results might lead to the erroneous conclusion that a
statistically significant difference exists between the study
groups when in reality it does not (Table 1, cell B).
2. The results might lead to the erroneous conclusion that there
is no significant difference between the study groups when in
reality a difference exists (Table 1, cell C).The first situation
represents false-positive result and is called a type I error. The
bound that we put on the probability of committing a type I
error is named alpha [9, 11]. Alpha is also referred to as the
level of statistical significance or significance level. Situation 2
represents a false-negative result and is called a type II error.
The probability of committing a type II error is referred to as
beta [9, 11, 12].
An alpha of 0.05 is commonly assumed in medical research. This
means that a 5% chance of obtaining a false-positive result (a
statistically significant difference if in reality no difference exists)
is considered acceptable. Alpha is the benchmark to which p
values are compared. If the p value is larger than alpha, a result is
said to be nonsigniﬁcant. On the other hand, if the p value is
smaller than the benchmark alpha, the findings are statistically
signiﬁcant. In other words, alpha is the threshold p value below
which a result is called statistically significant. Beta, the false-
negative rate, is complementary to the power of a study. Although
it could be assumed that both type I and type II errors are set at
the same level of 5%, a false-positive finding is often considered
potentially more harmful than a false-negative result. Thus, in
medical science, beta is commonly set between 0.2 and 0.1. Type
II errors of 0.2, 0.15, and 0.1 correspond to a power of 80% (1.0–
0.2), 85% (1.0–0.15), or 90% (1–0.10), respectively. Ideally, both
alpha and beta would be set at 0 to avoid both false-positive and
false-negative findings. This would, however, result in an pro-
hibitively large sample size, rendering any trial unfeasible. For a
patient sample of a given size, there is always a trade-off between
alpha and beta: the more stringent the alpha (the lower the false-
positive rate), the higher the beta (increased rate of false-negative
results, lower power), and vice versa [9, 13]. In general, one
should choose a small alpha level if avoiding a false-positive result
is particularly important (e.g., comparing the efficacy of a new
chemotherapy regimen with serious adverse effects against an
existing regimen that is efficient and well supported by patients).
Similarly, a small beta level should be chosen if obtaining a false-
negative result would be deleterious; for example, if an investi-
gator wants to demonstrate the superiority of a new, less invasive
surgical procedure over an established procedure that is associ-
ated with considerable short- and long-term sequelae. The false
conclusion that the new procedure is not as effective as the
standard procedure would put new patients at risk of suffering
worse outcomes [6].
Power
Power is defined as the probability of finding a statistically sig-
nificant result (of rejecting the null hypothesis) in a study if the
populations are truly different [9]. The choice of adequate power
in a study is critical, as investigators and funding agencies must be
confident that an existing difference in the overall patient popu-
lation can be detected using the study sample. For instance, if the
power in a randomized controlled trial is set at 90% (beta of 10%)
and a true difference exists between the study arms in the overall
patient population, we would be able to detect that difference in 9
of 10 cases if the trial were repeated an infinite number of times.
The power of a study is intrinsically linked to the sample size [14]:
the larger the sample size, the higher the power. Quite often small
studies do not find statistically significant differences. It is then
unclear whether there is truly no difference between the treat-
ment options or the sample size was prohibitively small to provide
sufficient evidence for a statistically significant difference [4]. This
represents one of the most important concepts of this article and
is worth repeating: To interpret appropriately an investigation
that does not find a statistically significant difference between the
study groups, it is critically important to check if a sample size was
computed and whether a sufficient amount of patients were en-
rolled and evaluated [15]. Raising the following question is
imperative: Based on the actual sample size, the observed dif-
ference between the study groups, and the chosen alpha level,
what was the power of the investigation [1, 5]? Studies that nei-
ther found statistically significant difference between the out-
comes nor enrolled a sufficiently large number of patients should
be considered inconclusive (not negative), and the results should
be interpreted (at best) as hypothesis generating but not as
hypothesis testing [15]. Unfortunately, there is a plethora of
studies in the medical literature that were clearly underpowered
while claiming that there was no statistically significant difference
in outcomes [2, 3, 12, 15, 16], an erroneous and potentially
harmful conclusion. Goodman and Berlin emphasized the
importance of displaying 95% confidence intervals of the observed
difference between groups to enable the reader to more accu-
rately interpret ‘‘negative’’ studies [17].
Table 1. Type I and type II errors.
Truth in the overall patient population
Results of the study Treatment difference No treatment difference
Treatment difference Correct conclusion A B Type I error (false-positive result)
No treatment difference Type II error (false-negative result) C D Correct conclusion
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In addition to the sample size, the power of a study depends on
the following factor [9, 12].
1. The extent of the true difference in the overall patient popu-
lations from which the sample has been drawn
2. The alpha level (accepted rate of false-positive results)
3. Variability (standard deviation) of continuous outcomesThe
power of the study increases with larger sample sizes, larger
true differences in the outcomes between the populations from
which the patient samples have been drawn, higher acceptance
of false-positive results, and less variability in the outcomes.
Effect Size
For sample size computations, investigators start by defining a
clinically meaningful difference in outcomes (synonym: end-
points) between treatment A and B (called effect size or delta),
which is believed to be true for the overall patient population [14,
18]. Although a study often evaluates different outcomes, one
should be chosen for consideration as the most relevant one (the
primary outcome, e.g., overall survival in a randomized phase III
trial); and the sample size computations must be based on an
estimated difference of the primary endpoint. On rare occasions,
two or even more outcomes are considered to be of similar rel-
evance. In that scenario, the sample size should be computed for
all outcomes and the largest resulting sample size chosen for the
study [5, 15].
It is often a challenging undertaking to estimate the magnitude
of the difference in outcomes because the true value of the effect
size might be totally unknown [19]. Clearly, if the effect size were
already known, there would be no point in performing the study.
Ideally, the estimated difference between outcomes is based on
the preliminary data gained from pilot studies [20] or retrospec-
tive reviews, but is sometimes specified according to clinical
intuition [1]. The smaller the expected difference in the outcome,
the larger is the sample size (Table 2). However, this difference
should be sufficiently large to result in a change in clinical practice
[18]. For instance, suppose a study evaluating whether pancrea-
ticoduodenectomy plus extended lymphadenectomy (the new
treatment) leads to improved overall survival compared to pan-
creaticoduodenectomy alone (standard treatment) in patients
with potentially curable pancreatic cancer. Let us further assume
that the median overall survival after the standard treatment is
known to be 24 months. It would certainly be irrelevant if the new,
more extensive surgical therapy led to a median overall survival of
25 months. Suppose, however, that the investigator believes that
the median overall survival due to more extensive surgery will be
36 months. This would represent a clinically relevant difference
that would affect the current standard of care. The investigator
would then power the study for a difference of 12 months
(36 ) 24 months).
Variability in Outcomes
If the endpoint under investigation is a continuous variable, the
investigator must define not only a clinically relevant difference
between the outcomes but also the variability (standard deviation,
data scatter) of the outcome. The larger the variability in out-
comes, the more patients needed to prove that the difference in
outcomes is statistically significant (Table 3). As for the estima-
tion of difference in outcomes, the assumption of outcomes var-
iability ideally is based on data of previous studies of similar
patient populations or data from the medical literature. This
obviously does not apply to comparisons of percentages.
How to Minimize Sample Sizes?
It is intuitively obvious that large sample sizes are unequivocally
associated with increased costs and consumption of resources
when performing clinical trials. What can you do if after com-
puting the sample size based on the above-mentioned factors, you
realize that it is impracticably large? To answer this relevant
question it is worth reviewing the parameters affecting the sample
size. The sample size of a study is large if [5]
1. The estimated effect size is small
2. The type I error (rate of false positives) is small
3. The type II error (rate of false negatives) is small (equivalent
to high power)
4. The estimated variability of the outcomes is large
6. The alternative hypothesis is formulated two-sidedKnowing
the association of these parameters and the sample size, the
Table 2. Sample size computations for a hypothetical randomized clinical trial comparing surgery alone versus neoadjuvant radiotherapy plus surgery
for esophageal cancer.
Expected 2-year overall survival of
patients undergoing surgery alone (%)
Expected 2-year overall survival of
patients undergoing neoadjuvant
radiotherapy plus surgery (%) Alpha Power (%) Total sample size
40 80 0.05 80 32
40 80 0.05 90 44
40 70 0.05 80 63
40 70 0.05 90 84
40 60 0.05 80 146
40 60 0.05 90 196
40 50 0.05 80 587
40 50 0.05 90 785
40 45 0.05 80 2324
40 45 0.05 90 3111
All sample size computations are based on equal percentages of patients in both groups, a type I error probability of 0.05 (two-sided), a projected
accrual period of 2 years, and a minimum follow-up period of 2 years.
There is suggestive evidence in the medical literature that neoadjuvant radiotherapy for esophaged cancer patients might be beneficial. Let us say
that we want to design a study evaluating whether adjuvant radiotherapy plus surgery prolongs overall survival versus surgery alone. Table 1 displays
sample size computations that would answer the same research question using different overall survival and power estimates. It is important to realize
that the sample sizes are highly dependent on the assumed estimated difference in survival rate and the chosen power.
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investigator should critically review whether one or several of
them could be changed. Is the estimated effect size unrea-
sonably small? Could the type I or type II error be increased
without either putting patients at risk or affecting the meth-
odologic rigor of the study? Can the measurements be done
with greater precision to diminish the variability (noise) in
outcomes? Is there sound evidence that allows the choice of a
one-sided instead of a two-sided alternative hypothesis?
If none of the above-mentioned parameters can be changed, the
following alternatives was result in a decreased sample size.
1. Use continuous instead of dichotomous (yes/no) endpoints:
Some variables can be expressed as either continuous or
dichotomous (yes/no) endpoints. If the choice of a continuous
endpoint is possible, it usually results in a smaller sample size
compared with dichotornous endpoints [11], as the collapse of
continuous data into two categories is associated with loss of
information. Suppose that in a randomized clinical trial we are
comparing two neoadjuvant treatments for advanced-stage
rectal cancer and that one outcome is the carcinoembryonic
antigen (CEA) level after therapy. If we compare the per-
centage of patients with normal CEA levels (a dichotomous
outcome: normal versus abnormal), the sample size is larger
than if absolute CEA levels (continuous outcome) are com-
pared.
2. Use a paired instead of an unpaired data analysis: A paired (or
clustered) data analysis should be used in the following sit-
uations: 2 (a) if two or more measurements are done with the
same subjects (e.g., before and after an intervention) [20]; (b)
if subjects are matched pairs or clusters (e.g., if for each
patient in a certain sample another patient with similar
characteristics (e.g., age, gender, race) has been assigned in a
comparison sample, or if there are natural clusters such as
members within families) [20]. The use of a paired data
analysis results in smaller sample sizes compared with non-
paired data analysis. The mathematical explanation of this
phenomenon is beyond the scope of the present article.
However, it is intuitive that if each patient serves as his/her
own control or that if you compare patients with similar
characteristics (in the matched study design), the between-
patient variability is decreased. In paired data situations a
paired test (e.g., paired t-test, repeated-measures ANOVA,
McNemars test.) may be used yielding greater power than
with the corresponding nonpaired test.
3. Use a more common outcome or a compared outcome: The
power of the study depends more on the number of patients
with a certain outcome (event) than on the total number of
subjects [15, 21]. When the computed sample size seems pro-
hibitively large, one could attempt to choose a more common
outcome. A simple way to increase the occurrence of an out-
come (e.g., death) is to enroll patients with a higher risk of
experiencing this outcome. If a researcher evaluates a new
investigational therapy for melanoma, and overall survival is
the primary endpoint, she could choose to enroll only stage III
and IV patients who are at greater risk of experiencing the
outcome (death) than are early-stage patients. Moreover, the
number of events could be increased by extending the period
of follow-up, which again lowers the sample size [22, 23].
However, prolonging the follow-up of patients leads to higher
costs and may be associated with an increased rate of dropouts.
Finally, a composite outcome could be chosen. Suppose that
the primary endpoint of a trial comparing the impact of two
treatments in patients with metastatic colon cancer is disease
regression. Further suppose that the sample size was prohibi-
tively large to perform the trial. To increase the feasibility of
the study, one could choose a composite outcome, such as
(disease regression + stable disease).It should be emphasized,
however, that an investigator should only change the param-
eters affecting the sample size if there is evidence to support
this change. Decreasing the sample size for the sake of feasi-
bility at the expense of making unrealistic assumptions or
compromising the relevance of the research question results in
an underpowered or irrelevant trial that is both wasteful and
unethical.
Caveats of Sample Size Computations
Performing sample size computations represents an important
and delicate step when designing a study. Herein, we briefly
summarize some caveats regarding sample size computations.
1. The most common error regarding sample size computations is
performing them too late in the process of developing the
study. Sample size computations should be done during the
very early planning phases of a study, when fundamental
changes of the design are still possible [5]. Also, sample size
computations often reveal that the number of patients needed
is impracticably large, thus compromising the feasibility of the
investigation.
2. It might be wise to include more patients than the minimum
number of participants computed. This depends on the esti-
mated percentage of dropouts or those lost-to-follow-up. The
Table 3. Hypothetical randomized clinical trial comparing quality of life 2 weeks postoperatively in patients randomized to open versus laparoscopic
sigma resection for diverticulitis.
QoL open QoL lap SD Power (%) Hypothesis Total no. of patients
50 60 5 80 Two-sided 12
50 60 5 80 One-sided 10
50 60 15 80 Two-sided 74
50 60 15 80 One-sided 58
50 60 30 80 Two-sided 286
50 60 30 80 One-sided 226
Suppose that we want to design a prospective randomized trial comparing quality of life 2 weeks postoperatively in patients randomized to open
versus laparoscopic sigma resection for diverticulitis. The quality of life assessments are done on an imaginary questionnaire ranging from 0 (worst
imaginable quality of life) to 100 (excellent quality of life).
Note that the sample size increases with greater data scatter (standard deviation) and decreases if the hypothesis is one-sided.
QoL: quality of life; open: open operation; Lap: laparoscopic surgery.
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sample size computations reflect the number of evaluable pa-
tients at the end of the study. If the sample size computations
do not take this into consideration, the study is underpowered
if some patients do not finish the trial.
3. It is imperative that the authors of a clinical trial report the
parameters upon which the computed sample size is based [15,
16, 24]. Despite this, many investigators fail to do so [2, 3, 12,
25]. If no information about power calculations is reported, the
reader does not know if: (a) no sample size requirement was
computed; (b) the investigators were unable to accrue the
initially computed patient number; (c) the trial was extended
beyond the initially computed sample size to obtain higher
statistical power; or (d) the investigators stopped the trial
earlier than anticipated because the interim results were
favorable [25].
4. An important caveat regarding sample size computations
represents the misinterpretation between number of patients
and number of events [15]. Some mathematic formulas provide
the investigator with the number of events (e.g., number of
needed death in a trial evaluating overall survival) rather than
with the total number of patients needed. Let us assume that
we estimate that the overall survival rate is 30% at the end of a
planned trial and that the number of events needed to show a
statistically significant difference is 200. If we misinterpreted
this number as the total number of patients, we would end up
with a dramatically underpowered study, a grave error that
must be avoided at any costs. Verifying sample size calcula-
tions with a statistician is strongly recommended to double
check whether the sample size refers to total number of pa-
tients or number of required events.
Conclusions
Understanding the parameters that affect sample sizes is
invaluable in the design of clinical studies as well as essential to
critical assessment of scientific findings and their implementa-
tion in clinical practice. It is hoped that this review enables
surgeons to understand the ingredients necessary for accurate
sample size computations and facilitates their communication
with medical epidemiologists and statisticians, with the ultimate
goal of creating better surgical trials. Clearly, sample size mat-
ters.
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